Seres Therapeutics (MCRB) SER-287 Phase 1B Topline Study Results In Patients With Mild-To-Moderate Ulcerative Colitis - Slideshow

|
About: Seres Therapeutics (MCRB)
by: SA Transcripts

The following slide deck was published by Seres Therapeutics in conjunction with this event.